RadNet (RDNT) Slid on Concerns over the Potentially Disruptive Impact of AI

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and the 3.96% decline for the Russell 3000 Index (the Index). The Fund appreciated 9.39% on an annualized basis since its inception, compared to the 8.97% gain for the Benchmark and the 13.26% gain for the Index. The disappointing stock selection drove the Fund’s underperformance in the quarter. Despite recent challenges, the Fund believes the long-term outlook for health care remains positive due to factors including an aging population, rising chronic disease rates, advances in biotechnology, and increased health care spending. In addition, please check the Fund’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Baron Health Care Fund highlighted stocks like RadNet, Inc. (NASDAQ:RDNT). RadNet, Inc. (NASDAQ: RDNT) is a leading provider of outpatient diagnostic imaging services, including MRI, CT, PET, ultrasound, and X-ray. On May 1, 2026, RadNet, Inc. (NASDAQ:RDNT) closed at $56.85 per share. One-month return of RadNet, Inc. (NASDAQ:RDNT) was 3.25%, and its shares gained 7.00% over the past 52 weeks. RadNet, Inc. (NASDAQ:RDNT) has a market capitalization of $4.45 billion.

Baron Health Care Fund stated the following regarding RadNet, Inc. (NASDAQ:RDNT) in its Q1 2026 investor letter:

“RadNet, Inc. (NASDAQ:RDNT) is the largest U.S. operator of freestanding imaging centers and a leading radiology software provider through its Deep Health subsidiary. Despite a fourth-quarter beat and above consensus 2026 guidance, shares fell amid widespread investor concerns about the potentially disruptive impact of AI on software companies. This was likely exacerbated by RadNet’s recently announced $270 million acquisition of Gleamer, a Paris-based X-ray-focused software company. The stock was also weighed down by severe weather in the first quarter, which negatively impacted volumes. We think AI will enhance, rather than replace, RadNet’s software solutions and contribute to internal efficiencies that support margin expansion. As a result, we remain positive on RadNet and believe radiology volumes will continue to increase based on favorable demographics, a shift toward lower-cost outpatient settings, and expanded clinical applications driven by newer, more sophisticated modalities such as PET-CT.”